PIK3CA and gastric cancer: Moreover, Zhang et al. [56] used a novel dual PI3K/mTOR inhibitor, NVP-BEZ235 (BEZ235), with paclitaxel and observed additive anti-proliferative and pro-apoptotic effects to enhance the nanoparticle albumin–bound (nab)–paclitaxel response in gastric cancer cells.